Company news

Prelude Therapeutics Incorporated news in 2022

Prelude Therapeutics Incorporated's news releases, calls and decks from 2022, newest first.

View company

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

October 17, 2022

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

September 5, 2022

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

August 8, 2022

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

May 9, 2022

Prelude Therapeutics Reports Full Year 2021 Financial Results

March 15, 2022

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

March 10, 2022

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

March 8, 2022

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

March 8, 2022

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

January 3, 2022

Decks in 2022